Form 4: ANAB Director Sells Shares Under 10b5-1 Plan

AnaptysBio Director Hollings Renton exercised stock options and sold a portion of the resulting common stock shares under a pre-arranged 10b5-1 trading plan.

Summary

• Director Hollings Renton exercised options to acquire 10,231 shares of AnaptysBio, Inc. common stock at an exercise price of $6.93 per share.
• The exercised options were granted on August 14, 2015, fully vested, and set to expire on August 13, 2025.
• Concurrently, Mr. Renton sold a total of 10,231 shares, comprising 3,110 shares at a weighted average price of $19.44 (ranging from $19.375 to $19.46) and 7,121 shares at a weighted average price of $19.696 (ranging from $19.48 to $20.46).
• These sales were executed under a Rule 10b5-1 trading plan adopted on March 14, 2024, designed to facilitate the orderly exercise and sale of expiring options.
• Following these transactions, Mr. Renton beneficially owns 4,965 shares of common stock directly.
• Mr. Renton retains additional options to purchase up to 101,820 shares of common stock, which vest according to their terms.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a director selling shares can be seen negatively, the fact that it's under a pre-arranged 10b5-1 plan for expiring options, and the director still retains a significant number of options, mitigates negative sentiment. It's a routine equity management event.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a systematic approach to managing equity rather than a reaction to new, non-public information.
• The director exercised options that were significantly in-the-money ($6.93 exercise price vs. ~$19.50 sale price), demonstrating the value of the long-term equity incentive.
• The director still holds 4,965 shares directly and substantial additional options (101,820 shares), maintaining a vested interest in the company's future performance.

Negatives

• A director selling shares, even under a 10b5-1 plan, reduces their direct equity stake in the company.

Future Outlook

The filing indicates that the director holds additional stock options that vest according to their terms, suggesting continued long-term equity incentives.

Management Comments

• The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024.
• Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options, including the options exercised and sold under this Form 4, which have an expiration date of August 13, 2025.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, specifically related to equity compensation management. It does not provide information directly related to broader industry trends or competitive landscape, but reflects standard practices for executives managing expiring stock options in the biotechnology sector.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be perceived as a slight negative, but the pre-arranged nature (10b5-1 plan) and the retention of significant options mitigate concerns about a lack of confidence. It's a routine part of equity compensation management.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.
• Future vesting of the remaining 101,820 stock options held by the Reporting Person.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director exercised expiring stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan. This type of transaction is common for managing equity compensation and does not typically signal a change in the company's fundamental outlook or the insider's confidence. The director still retains a substantial number of unexercised options, indicating continued alignment with shareholder interests. Therefore, this specific filing does not provide new information that would warrant a change in investment thesis, suggesting a 'hold' recommendation.

Keywords

ANAPTYSBIO, ANAB, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1, Director Share Sale, Equity Compensation, Biotechnology